[29][30][31][32][33][34]. When the reference INR was low, the Hemochron devices would not result in appropriate dose increases in 52% of cases (95% CI 48-56), placing these patients at risk for a significant adverse drug event. Conclusions: Our novel, clinically relevant analysis revealed previously undetected deficiencies in our POC INR devices, and our approach should be adopted by industry, regulators, and institutions.